Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 2, 2015, Pages G151-G158

  Okubo, Hirofumi ^a   Nakatsu, Yusuke ^a   Sakoda, Hideyuki ^b   Kushiyama, Akifumi ^c   Fujishiro, Midori ^b   Fukushima, Toshiaki ^a   Matsunaga, Yasuka ^a   Ohno, Haruya ^d   Yoneda, Masayasu ^d   Kamata, Hideaki ^a   Shinjo, Takanori ^a   Iwashita, Misaki ^a   Nishimura, Fusanori ^a   Asano, Tomoichiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c INSTITUTE FOR ADULT DISEASES   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Glucagon like peptide 1; Gut microbiota; Inflammation; Mosapride citrate; Nonalcoholic steatohepatitis

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MOSAPRIDE; BENZAMIDE DERIVATIVE; LACTIC ACID; MORPHOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIFIDOBACTERIUM; COLITIS; CONTROLLED STUDY; GASTROINTESTINAL MOTILITY; GLUCAGON BLOOD LEVEL; INTESTINE FLORA; LACTIC ACID BACTERIUM; LACTOBACILLUS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; FECES; GASTROINTESTINAL TRACT; INFLAMMATION; LIVER; LIVER CIRRHOSIS; METABOLISM; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN DEFICIENCY;

ANIMALS; BENZAMIDES; CHOLINE DEFICIENCY; FECES; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; INFLAMMATION; LACTIC ACID; LIVER; LIVER CIRRHOSIS; MICE, INBRED C57BL; MORPHOLINES; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84921466000     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00198.2014     Document Type: Article

References (43)

1. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 691–701, 2010.
2. Ahrne S, Hagslatt ML. Effect of lactobacilli on paracellular permeability in the gut. Nutrients 3: 104–117, 2011.
3. Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 146: 1564–1572, 2014.
4. Aoki K, Kamiyama H, Masuda K, Togashi Y, Terauchi Y. Mosapride citrate, a 5-HT(4) receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men. Endocrine J 60: 493–499, 2013.
5. Bajaj JS, Hylemon PB, Younossi Z. The Iintestinal microbiota and liver disease. The Am J Gastroenterol Suppl 1: 9–14, 2012.
6. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 9: e87488, 2014.
7. Bienenstock J, Gibson G, Klaenhammer TR, Walker WA, Neish AS. New insights into probiotic mechanisms: a harvest from functional and metagenomic studies. Gut Microbes 4: 94–100, 2013.
8. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091–1103, 2009.
9. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 59: 328–339, 2014.
10. Chassaing B, Gewirtz AT. Gut microbiota, low-grade inflammation, and metabolic syndrome. Toxicol Pathol 42: 49–53, 2014.
11. Chen X, Zhang C, Zhao M, Shi CE, Zhu RM, Wang H, Zhao H, Wei W, Li JB, Xu DX. Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice. J Pineal Res 51: 416–425, 2011.
12. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54: 133–144, 2011.
13. Delzenne NM, Neyrinck AM, Backhed F, Cani PD. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7: 639–646, 2011.
14. Dicksved J, Schreiber O, Willing B, Petersson J, Rang S, Phillipson M, Holm L, Roos S. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One 7: e46399, 2012.
15. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Intl 28: 1026–1033, 2008.
16. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497–509, 1956.
17. Fujisawa M, Murata T, Hori M, Ozaki H. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterol 45: 179–186, 2010.
18. Ida Y, Hosoe N, Imaeda H, Bessho R, Ichikawa R, Naganuma M, Kanai T, Hibi T, Ogata H. Effects of the oral administration of mosapride citrate on capsule endoscopy completion rate. Gut Liver 6: 339–343, 2012.
19. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, Wells JM. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 298: G851–G859, 2010.
20. Kato S, Matsuda N, Matsumoto K, Wada M, Onimaru N, Yasuda M, Amagase K, Horie S, Takeuchi K. Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: proulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors. Pharmacol Res 66: 226–234, 2012.
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41: 1313–1321, 2005.
22. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM, Fatty Liver Subgroup of the Look ARG. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33: 2156–2163, 2010.
23. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 57: 545–553, 2012.
24. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharmaceutical Design 19: 5250–5269, 2013.
25. Matsuda K, Tsuji H, Asahara T, Matsumoto K, Takada T, Nomoto K. Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Appl Environ Microbiol 75: 1961–1969, 2009.
26. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10: 656–665, 2013.
27. Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, Vecchio FM, Gasbarrini A, Gasbarrini G. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 69: 225–228, 2004.
28. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a micro-biota-driven disease. Trends Endocrinol Metab 24: 537–545, 2013.
29. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol 12: 562–568, 2004.
30. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298: G807–G819, 2010.
31. Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y, Chonan O, Iwashita M, Nishimura F, Asano T. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol 305: G911–G918, 2013.
32. Parlevliet ET, Wang Y, Geerling JJ, Schroder-Van der Elst JP, Picha K, O’Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H, Rensen PC. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One 7: e49152, 2012.
33. Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 28: 427–433, 2008.
34. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146: 1513–1524, 2014.
35. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28, Suppl 1: 68–76, 2013.
36. Taniyama K, Makimoto N, Furuichi A, Sakurai-Yamashita Y, Nagase Y, Kaibara M, Kanematsu T. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxytryptamine4 receptor, in gastrointestinal motility. J Gastroenterol 35: 575–582, 2000.
37. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 121: 2126–2132, 2011.
38. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 302: G762–772, 2012.
39. Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 53: 606–613, 2010.
40. Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Brit J Pharmacol 171: 723–734, 2014.
41. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 206–211, 2001.
42. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288: 25088–25097, 2013.
43. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57: 601–609, 2013.